Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

The FDA has approved Medtronic plc's (NYSE: MDT) InterStim X, the next generation of the InterStim portfolio's recharge-free device. InterStim systems deliver sacral neuromodulation (SNM) therapy.

InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, ...

World’s Smallest Rechargeable Bladder/Bowel Control System — InterStim Micro — Features Trusted MRI Technology for Full-Body 1.5 and 3 Tesla MRI Scans Only Medtronic Offers Patients Personalized ...

Broward Health Medical Center is now offering the InterStim X system from Medtronic, a cutting-edge treatment for patients with bladder and bowel control conditions such as urinary and fecal ...

Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals that ...

Medtronic plc has won U.S. FDA approval of its Interstim Micro rechargeable sacral nerve stimulator and Interstim Surescan MRI leads for the treatment of urinary and bowel dysfunctions. The new ...

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim® Therapy for Bowel Control. InterStim Therapy, previously ...

announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...